WebSite > Enki Biopharmaceuticals(Shanghai) Limited

Enki Biopharmaceuticals(Shanghai) Limited

  • Company Name Enki Biopharmaceuticals(Shanghai) Limited
  • Tel 021-57680965
  • Email yusu@enkibiopharma.com
  • WebSite http://www.enkibiopharma.com/
  • CB Index 55
  •       Enki Biopharmaceuticals (shanghai) Limited is professional company that dedicate in research and development, production and marketing of pharmaceutical intermediates and API. Our lab and factory is located in Hebei Province. Company is taking the leading position in technology research and development, with high value-added and high technology content of pharmaceutical intermediates/chiral compounds, on the basis of the development and production of active pharmaceutical ingredients (APIs) for end products, with industrialization as the ultimate goal, building chiral synthesis, chemical/enzyme catalysis, core technology of clean production process. Company insists on taking market as the guide, innovation as the support, the industrialization as the target of the management idea, abide by the "Focus, Profession, innovation, Innovation, Win-Win" spirit of enterprise, in order to "create value for customers, creating opportunities for staff, for human to create health" for the purpose, to provide high quality products to our clients and the best quality service, achieve win-win with customers, and employee development, and social harmony.
Enki Biopharmaceuticals(Shanghai) Limited Product List
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Febuxostat
  • MF C16H16N2O3S
  • CAS 144060-53-7
  •  
  •  
  •  
  •  
  •  
  • Product Name Entrectinib
  • MF C31H34F2N6O2
  • CAS 1108743-60-7
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Tolvaptan
  • MF C26H25ClN2O3
  • CAS 150683-30-0
  •  
  •  
  • Product Name Brigatinib
  • MF C29H39ClN7O2P
  • CAS 1197953-54-0
  •  
  •  
  •  
  •  
  • Product Name Crisaborole
  • MF C14H10BNO3
  • CAS 906673-24-3
  •  
  •  
  •  
  •  
  •  
  •  
  •